Kite-Shaped Molecules Block SARS-CoV-2 Cell Entry at a Post-Attachment Step

Area of Science:

• Virology
• Drug Discovery
• Medicinal Chemistry

Background:

• Antiviral small molecules for treating coronavirus infections are limited.
• Drug development timelines are lengthy, necessitating drug repurposing strategies.
• Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a significant global health threat.

Purpose of the Study:

• To screen FDA-approved drugs for potential SARS-CoV-2 antiviral activity.
• To identify and characterize novel antiviral compounds through drug repurposing.
• To explore the potential of existing medications in combating current and future coronavirus outbreaks.

Main Methods:

• Screening of FDA-approved compounds using a SARS-CoV-2 pseudovirus system.
• Determination of inhibitory activity (IC50 values) for identified compounds.
• Pharmacophore modeling to predict antiviral activity based on molecular structure.

Main Results:

• Identification of structurally related, "kite-shaped" compounds with moderate antiviral activity (IC50: 2-5 μM).
• Demonstration of specificity for SARS-CoV-1 and SARS-CoV-2, targeting early viral entry but not attachment.
• Prevention of viral infection in both kidney- and lung-derived human cell lines.

Conclusions:

• Repurposing existing drugs offers a viable strategy to accelerate the development of SARS-CoV-2 treatments.
• The identified compounds show promise for treating coronavirus infections due to their specific mechanism of action and efficacy in human cell lines.
• The developed pharmacophore accurately predicts antiviral activity, aiding in the discovery of new therapeutic agents.